№ lp_1_2_23489
File format: docx
Character count: 9190
File size: 46 KB
This document provides detailed information about the meningococcal disease, related vaccination requirements, and the waiver process for students at colleges and residential schools in Massachusetts, offering guidance for both students and their parents or legal guardians.
Year:
2023
Region / City:
Massachusetts
Topic:
Meningococcal disease, Vaccination requirements
Document type:
Health advisory
Institution:
Massachusetts Department of Public Health
Author:
Massachusetts Department of Public Health
Target audience:
College and residential school students, Parents and legal guardians
Period of validity:
Ongoing
Approval date:
Not specified
Amendment date:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Reference no:
Hib/MenC PGD
Version no:
v6.0
Valid from:
1 July 2025
Expiry date:
30 April 2026
Authorising organisations:
UK Health Security Agency (UKHSA)
Target audience:
Registered healthcare practitioners
Responsible body:
UKHSA
Note:
Amendment history
v1.0 and v2.0:
See previous versions of this PGD template for details (19 January 2016 to 23 April 2018)
v3.0:
PHE Hib/MenC PGD amended to: include vaccination of individuals for the prevention of secondary cases of meningococcal group C disease (24 April 2018)
v4.0:
PHE Hib/MenC PGD amended to: remove reference to individuals with an underlying medical condition (5 March 2020)
v5.0:
UKHSA Hib/MenC PGD amended to: include minor rewording of standard text, layout and formatting changes (4 May 2022)
v6.0:
UKHSA Hib/MenC PGD amended to: include minor rewording, updated references, and changes to the childhood immunisation schedule (2 June 2025)
Developed by:
Christina Wilson (Lead Pharmacist), Professor Shamez Ladhani (Paediatric Infectious Diseases Consultant), David Green (Nurse Consultant for Immunisation Programmes)
Peer-reviewed by:
UKHSA Immunisations PGD Expert Panel
Date approved:
2 June 2025
Year:
2025
Region / City:
United Kingdom
Topic:
Meningococcal Disease, Ciprofloxacin, Public Health
Document Type:
Clinical Guidance
Organization / Institution:
UK Health Security Agency (UKHSA)
Author:
Shilan Ghafoor, Dr. Shamez Ladhani, Kate Wedgwood
Target Audience:
Healthcare Practitioners, Public Health Authorities
Period of Validity:
From 20 October 2025
Approval Date:
10 October 2025
Expiry Date:
19 October 2028
Review Date:
19 October 2027
Year:
2025
Region / City:
England
Topic:
Immunisation, Vaccination
Document Type:
Patient Group Direction (PGD)
Organization:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Professor Shamez Ladhani, David Green
Target Audience:
Healthcare practitioners (registered)
Period of validity:
1 August 2025 - 1 August 2027
Approval Date:
9 June 2025
Review Date:
1 February 2027
Amendment Date:
7 July 2025
Year:
2025
Region / City:
England
Topic:
Meningococcal Disease, Vaccination
Document Type:
Patient Group Direction (PGD)
Organization / Institution:
UK Health Security Agency (UKHSA)
Author:
UK Health Security Agency
Target Audience:
Healthcare practitioners, NHS organizations
Period of validity:
1 July 2025 - 28 February 2028
Approval Date:
2 June 2025
Amendments Date:
11 December 2024, 7 December 2022, 28 January 2021, 21 December 2018, 24 April 2018, 3 February 2017, 21 July 2015
Note:
Context
Year:
2025
Region / city:
England
Topic:
Vaccination
Document Type:
Patient Group Direction (PGD)
Authorizing Body:
UK Health Security Agency (UKHSA)
Target Audience:
Healthcare professionals involved in immunization
Validity Period:
31 July 2025 – 31 December 2027
Review Date:
30 June 2027
Amendment History:
v1.0 to v6.0
Approval Date:
2 June 2025
Year:
2024
Region / city:
England
Theme:
Vaccination, Meningococcal Disease
Document type:
Patient Group Direction (PGD)
Institution:
UK Health Security Agency (UKHSA)
Author:
Suki Hunjunt, Mary Ramsay, David Green
Target audience:
Healthcare practitioners
Period of validity:
From 28 February 2025 to 28 February 2028
Approval date:
11 December 2024
Revision date:
7 December 2022
Expiry date:
28 February 2028
Content changes:
Minor rewording and updates for clarity and consistency, updated qualifications and professional registration
Purpose:
Facilitates the administration of the meningococcal group B vaccine in individuals with increased risk from Neisseria meningitidis group B in the UK
Year:
2017
Region / city:
Australia
Theme:
Meningococcal Vaccination
Document Type:
Application for Vaccine Listing
Organization / institution:
National Immunization Program (NIP)
Author:
Pfizer Australia Pty Ltd
Target Audience:
Health professionals, adolescents, school-based vaccination program administrators
Validity Period:
Not specified
Approval Date:
29 August 2013
Amendment Date:
Not specified
Note:
Contextual description
Year:
2020
Region / City:
United Kingdom, London
Subject:
Meningococcal disease, vaccination
Document Type:
Research article
Institution:
St George’s University of London, Public Health England
Author:
Catherine Isitt, Catherine A Cosgrove, Mary E Ramsay, Shamez N Ladhani
Target Audience:
Healthcare professionals, researchers
Period of validity:
Ongoing
Date of approval:
2013
Date of modifications:
None specified
Year:
2017
Region / city:
Northern Territory, South Australia, Western Australia
Topic:
Meningococcal Vaccination
Document Type:
Health Information Sheet
Organization:
Western Australia Department of Health
Author:
Western Australia Department of Health
Target Audience:
Community members in remote regions of Western Australia
Effective Period:
Ongoing during the MenW outbreak response
Approval Date:
October 2017
Modification Date:
Not specified
Year:
2017
Country:
Australia
Programme:
Australian Meningococcal Surveillance Programme (AMSP)
Coordinating body:
National Neisseria Network
Funding body:
Australian Government Department of Health
Authors:
Monica M Lahra; Rodney Enriquez; CR Robert George
Subject:
Invasive meningococcal disease surveillance
Pathogen:
Neisseria meningitidis
Data sources:
National Neisseria Network laboratories; National Notifiable Diseases Surveillance System
Number of laboratory-confirmed cases:
374
Number of notified cases:
379
Primary serogroups reported:
B; W; Y; C
Peak incidence period:
1 July – 30 September 2017
Geographical coverage:
All Australian states and territories
Antimicrobial susceptibility testing:
Penicillin; Ceftriaxone; Ciprofloxacin; Rifampicin
Type of document:
Annual epidemiological surveillance report
Year:
2025
Region:
Washington State, United States
Topic:
Meningococcal disease and vaccination information
Document type:
Public health informational notice
Issuing organization:
Washington State Department of Health
Legal basis:
RCW 70.54.370
Target audience:
First-time enrolled college students
Purpose:
Required educational information prior to enrollment
Publication date:
April 2025
Document code:
DOH 348-636
Distribution format:
Electronic information notice
Subject areas:
Disease transmission, symptoms, treatment, prevention, vaccination
Related institutions:
Colleges and universities in Washington State
Year:
2023
Region / City:
Victoria, Australia
Topic:
Vaccination Program
Document Type:
Consent Form
Organization / Institution:
Department of Health, Victorian Government
Author:
Unknown
Target Audience:
Parents or guardians of students in secondary schools
Period of Effectiveness:
Ongoing
Approval Date:
October 2023
Date of Changes:
October 2023
Year:
2025
Region / city:
Global
Topic:
Vaccine Policy, Maternal Health, Group B Streptococcus
Document type:
WHO Guidance
Institution:
World Health Organization (WHO)
Author:
WHO ECVP
Target audience:
Policymakers, Vaccine Developers, Public Health Authorities
Period of validity:
Ongoing
Approval date:
March 11, 2025
Date of changes:
Not specified
Year:
2024
Region / city:
Global
Topic:
COVID-19 Vaccines
Document type:
Report
Author:
World Health Organization (WHO)
Target audience:
Health professionals, regulatory authorities
Approval date:
16 January 2024
Modification date:
N/A
Contextual description:
A report listing COVID-19 vaccines evaluated under the WHO EUL/PQ process, including details on manufacturers, vaccine types, shelf lives, and approval dates.
Year:
2026
Jurisdiction:
Victoria, Australia
Document type:
Report form
Subject:
Vaccine cold chain breach reporting
Issuing authority:
Department of Health, Victorian Government
Program:
Immunisation Program
Applicable vaccines:
Government funded vaccines and immunisation products
Target users:
Immunisation providers
Scope:
Cold chain breach events excluding delivery incidents
Temperature range reference:
+2°C to +8°C
Reporting method:
Email submission to Immunisation Program
Publication date:
January 2026
Publisher:
State of Victoria, Australia
Copyright holder:
Department of Health, Victoria
Note:
Year
Region / City:
Alabama
Theme:
Vaccine management, immunization program
Document Type:
Vaccine management plan
Organization / Institution:
Alabama Department of Public Health (ADPH)
Author:
Alabama Department of Public Health (ADPH)
Target Audience:
VFC providers, immunization staff
Effective Period:
Ongoing
Year:
2024
Region / City:
Victoria, Australia
Topic:
Immunisation
Document Type:
Official Information
Author:
Department of Health, State of Victoria
Target Audience:
Healthcare professionals, parents, and individuals requiring immunisation information
Period of Validity:
Not specified
Approval Date:
August 2024
Date of Changes:
Not specified
Year:
2025
Region / city:
Victoria, Australia
Subject:
Immunisation, Vaccines
Document type:
Health guideline
Organ / institution:
Department of Health and Human Services, Victorian Government
Author:
Victorian Government
Target audience:
Healthcare professionals, general public, parents, caregivers
Period of validity:
Until 2025
Approval date:
July 2025
Date of amendments:
Not specified
Year:
2023
Region / city:
Australia
Topic:
COVID-19 vaccines
Document type:
Clinical guidance
Organization / institution:
Australian Technical Advisory Group on Immunisation (ATAGI)
Author:
Australian Technical Advisory Group on Immunisation (ATAGI)
Target audience:
Healthcare professionals, general public
Period of validity:
Ongoing
Approval date:
October 2023
Date of changes:
Multiple updates since February 2021
Year:
2025
Region / City:
Northern Ireland
Topic:
COVID-19 vaccination, mRNA vaccines
Document Type:
Protocol
Organization / Institution:
Strategic Planning and Performance Group (SPPG), Public Health Agency (PHA)
Author:
Dr. Louise Herron, Mrs. Deirdre Ward, Mrs. Kathryn Turner
Target Audience:
Healthcare professionals administering COVID-19 mRNA vaccines
Period of Validity:
3 April 2025 to 30 June 2025
Approval Date:
3 April 2025
Note:
Change History
Version 1.0:
New national protocol for COVID-19 vaccines (adults) - 5 April 2024
Version 2.0:
Updated to reflect change in vaccine antigenic content - 16 September 2024
Version 3.0:
Updated eligibility criteria for Spring 2025 - 6 March 2025